|Bid||52.86 x 3000|
|Ask||53.01 x 1000|
|Day's range||50.20 - 53.70|
|52-week range||34.88 - 277.80|
|Beta (5Y monthly)||1.57|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Novavax (NASDAQ: NVAX) is a pandemic stock. Now it's down to $50, and the company's market cap is under $4 billion. Here are three arguments for buying Novavax stock and one reason for why you might want to avoid these shares.
As much as you might hate to hear this, stock market corrections and bear markets are a perfectly normal part of the investing cycle. Including the current bear market decline that the benchmark S&P 500 and tech-focused Nasdaq Composite are navigating their way through, the broader market has dropped by a double-digit percentage, on average, every 1.85 years since the beginning of 1950. Despite corrections being commonplace, the amount of time Wall Street spends in a bull market handily outpaces periods of pessimism.
Global biopharmaceutical company Sanofi (NASDAQ: SNY) encountered setbacks while developing its COVID-19 vaccine, and only this year reported results from late-stage clinical trials. Sanofi opted for the more traditional protein-based technology for its COVID-19 vaccine, Vidprevtyn, rather than the mRNA technology of Pfizer-BioNTech's Comirnaty and Moderna's Spikevax. The mRNA technology delivers genetic code instructing the body's cells to make the protein, while the more traditional approach produces the protein in a lab before injecting it into the body.